Arsenic Trioxide for Structural p53 Mutations

Inclusion Criteria: * Malignant solid tumors diagnosed histologically; * Solid tumor patients have no any standard choice after multiple line of therapy; * Next-generation Sequence showed TP53 mutation; * Expected survival ≥ 1 month; * ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL \<1.5 times the upper limit of normal (ULN); Liver ALT and AST \<2.5 × ULN and if liver metastases, ALT and AST \<5 × ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min * normal cardiac function * obtain informed consent Exclusion Criteria: * Patient still has standard treatment therapy based on NCCN guidance; * Patient can not comply with research program requirements or follow-up; * woman who are pregnant or breastfeeding; * allergic to any drug in protocol or with contraindications; * cannot understand or obey the protocol; * with a history of allergies or intolerability; * participate in other clinical trials meanwhile; * any situations that hinder trial existed;